# Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase

> **NCT02197650** · — · NO_LONGER_AVAILABLE · sponsor: **ERYtech Pharma**

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** suspension of erythrocytes encapsulating L-asparaginase

## Key facts

- **NCT ID:** NCT02197650
- **Lead sponsor:** ERYtech Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02197650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02197650, "Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02197650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*